Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CLBS 16

Next Previous
Drug Profile

CLBS 16

Alternative Names: Autologous stem cell therapy for coronary microvascular dysfunction - Lisata Therapeutics; CD34+ cell therapy - Lisata Therapeutics; CLBS-16; CLBS14-CMD; LSTA-16; XOWNA

Latest Information Update: 06 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Caladrius Biosciences
  • Developer Lisata Therapeutics
  • Class Cardiovascular therapies; Haematopoietic stem cells therapies; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cardiomyopathies

Most Recent Events

  • 02 Dec 2022 CLBS 16 is available for licensing as of 02 Dec 2022. https://www.lisata.com/clinical-stage-pharmaceutical-company/ (Lisata Therapeutics pipeline, December 2022)
  • 17 Oct 2022 Caladrius Biosciences terminates the phase IIb FREEDOM trial in Cardiomyopathies in USA (Intracoronary), as per sponsors decision (NCT04614467)
  • 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top